Regulatory coverage on Peptide News Digest tracks how the FDA, MHRA, EMA, and state agencies handle peptides — what they let through, what they pull, what they redefine.
The compounding fight has dominated 2025 and 2026. GLP-1s came off the FDA shortage list in early 2025; the agency moved compounded semaglutide and tirzepatide toward Category 2 on the 503A bulks list; and a wave of state legislation tried to either preserve or shut off telehealth access. The PCAC has spent meetings on BPC-157, GHK-Cu, and other research peptides that have built consumer demand without clinical infrastructure behind them.
Stories here name the agency, the substance, and the action. Browse the latest below, or jump to specific tags like #fda, #compounding, #peptide-policy, or #503a.
Moderna (NASDAQ: MRNA) announced Friday August 28, 2026 that the UK Medicines and Healthcare products Regulatory Agency (MHRA) authorized its updated Spikevax XFG-adapted COVID-19 mRNA vaccine for adults and children aged six months and older, priced for the autumn NHS vaccination program covering adults 65 and older, care home residents, health and social care workers, and clinically vulnerable groups. For the first time in the UK, the updated Spikevax vaccine will also be available to purchase privately for those not eligible for the NHS Autumn vaccination program, distributed through high street pharmacies, occupational health providers, and private healthcare companies. The authorization mirrors the FDA supplemental BLA approval that Pfizer-BioNTech received Wednesday August 27 for Comirnaty XFG, and lands as the roughly $2 billion August 27 Moderna convertible notes raise gears the company for cancer vaccine expansion.
President Trump announced Wednesday August 19, 2026 the formal nomination of Dr. Heidi Overton, a physician who currently works as deputy assistant to the president for domestic policy and formerly chief policy officer at America First Policy Institute, to serve as the next commissioner of the U.S. Food and Drug Administration. If confirmed by the U.S. Senate, Overton would take over from Kyle Diamantas (JD), who has served as acting commissioner since May 2026 following the departure of Marty Makary. Overton holds an MD from the University of New Mexico and a PhD in clinical investigation from Johns Hopkins Bloomberg School of Public Health, and served in the first Trump administration in the Office of American Innovation and Domestic Policy Council. She is Trump's third choice for the position after former Rep. Brad Wenstrup (R-Ohio) and acting Commissioner Diamantas both declined. The nomination matters for peptide-industry readers because the FDA rulemaking to translate the July 23-24 PCAC 6-peptide 503A recommendation (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon) into a proposed rule (and eventually a final rule) will run through Overton's tenure if she is confirmed; the February 2027 PCAC meeting on cathelicidin, GHK-Cu, dihexa acetate, melanotan II, and PEG-MGF falls entirely within the window.
The FDA approved Gilead Sciences (NASDAQ: GILD) Bixlenvo (bictegravir 75 mg / lenacapavir 50 mg, a once-daily single-tablet HIV regimen) on Thursday August 27, 2026 for adults with HIV-1 who are virologically suppressed on a stable antiretroviral regimen for at least 6 months and have no history of treatment failure or known resistance to bictegravir or lenacapavir. Approval was based on the Phase 3 ARTISTRY-1 and ARTISTRY-2 trials presented at CROI 2026, both of which met non-inferiority for virologic suppression at Week 48 with a tolerable safety profile. Lenacapavir is Gilead's first-in-class HIV-1 capsid inhibitor (already approved as long-acting subcutaneous Sunlenca), and Bixlenvo is the first oral single-tablet regimen anchored on capsid inhibition. Dosing requires a two-day initiation period with Sunlenca before switching to Bixlenvo alone. The approval extends the single-tablet regimen category to an estimated 5%+ of U.S. HIV-suppressed adults on complex multi-pill regimens who could not previously use one-tablet options.
Roivant Sciences (NASDAQ: ROIV) subsidiary Priovant Therapeutics announced FDA approval of Lisraya (brepocitinib 30 mg once daily, a first-in-class TYK2/JAK1 dual selective inhibitor) on Thursday August 27, 2026 for adults with dermatomyositis (DM), an autoimmune inflammatory myopathy with skin involvement and few effective targeted therapies. Approval was based on the 52-week Phase 3 VALOR trial (241 patients, the longest and largest interventional DM study), where 55% of Lisraya patients achieved moderate-or-better improvement on the Total Improvement Score with minimal-or-no steroid use versus 30% on placebo. VALOR results were published in NEJM in March 2026 with dermatology secondary endpoints in JAMA Dermatology in August 2026. List price is $35,000 for a 30-day supply, with a $0/month patient support program for eligible patients. Brepocitinib was originally discovered by Pfizer and licensed to Priovant. Not a peptide; the approval matters here because dermatomyositis is one of several autoimmune indications where peptide immunomodulators (thymalfasin, thymosin alpha-1 analogs) had been discussed in earlier decades before being displaced by targeted small-molecule and biologic approaches.
Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) announced Thursday August 27, 2026 FDA approval of the supplemental Biologics License Application for their 2026-2027 XFG-adapted Comirnaty (COVID-19 mRNA vaccine) for adults ages 65 and older and for individuals 5-64 with at least one underlying condition that puts them at high risk for severe COVID-19 outcomes. The XFG-adapted formula was designed to elicit strong immune responses against XFG, XFG.1.1, NB.1.8.1, PQ.17, PQ.2.8.1, and other contemporary lineages. Shipping to distribution centers began immediately after approval. The XFG-adapted authorization for the 2026-2027 respiratory season provides continuity with Pfizer-BioNTech's annual mRNA vaccine cadence and, indirectly, reinforces the manufacturing and lipid-nanoparticle infrastructure that Moderna is now leaning on for the intismeran neoantigen peptide-encoding cancer vaccine program.
ITM Isotope Technologies Munich SE's August 28, 2026 PDUFA target action date for 177Lu-edotreotide (ITM-11, a synthetic somatostatin-analog peptide-radioconjugate for gastroenteropancreatic neuroendocrine tumors) passed without an FDA approval decision, following the August 7, 2026 Complete Response Letter that cited Chemistry, Manufacturing, and Controls items and unresolved conditions at a third-party commercial manufacturing facility as the sole basis for the refusal. The FDA explicitly did not raise clinical or nonclinical safety or efficacy concerns, and did not request additional clinical data. ITM has stated it plans to resubmit the NDA once the manufacturing and facility items are addressed. The Phase 3 COMPETE trial (309 patients, first- or second-line inoperable progressive Grade 1 or Grade 2 GEP-NETs) had met its primary endpoint with a significant progression-free survival benefit over everolimus and a significantly higher objective response rate. The CRL is the second on the ITM-11 program and delays direct commercial competition with Novartis Lutathera (177Lu-DOTATATE, the incumbent peptide-radioconjugate for GEP-NETs).
The FDA on Wednesday August 26, 2026 approved Rasonque (daraxonrasib, a once-daily oral pan-RAS inhibitor developed by Revolution Medicines) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multi-agent chemotherapy. Approval was based on the Phase 3 RASolute 302 trial across 500 previously-treated patients showing median overall survival of 13.2 months on Rasonque versus 6.7 months on standard chemotherapy. The drug does not require a companion diagnostic and is approved for patients with or without an identifiable RAS tumor mutation. FDA granted Breakthrough Therapy and Orphan Drug designations plus Priority Review. Daraxonrasib is a small molecule and not a peptide; the approval matters to peptide-relevant readers because it hardens the oncology backdrop the neoantigen peptide vaccine class (Merck-Moderna intismeran, individualized long-peptide programs) is entering, and because it validates a new mechanism class in a tumor where five-year survival has stalled near 13% for two decades.
The Pharmacy Compounding Advisory Committee (PCAC) recommended on July 23-24, 2026 that six peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon) be added to the Section 503A Bulk Drug Substances List, with only Emideltide (DSIP) falling short. As of Wednesday August 26, 2026 the FDA has issued no proposed rule, no Federal Register notice, no interim enforcement policy, and no draft guidance following the recommendation. The agency stated it will 'review the record.' Removal from Category 2 in April did not automatically place these substances on the 503A bulks list; they exist in a regulatory gray zone until the PCAC recommendation is formally acted upon, a process that typically runs a year or longer. Warning-letter activity from CDER to compounding pharmacies is up roughly 50% year-over-year in FY 2025. The next PCAC meeting is scheduled for February 2027 to review cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and PEG-MGF.
Nicox SA (Euronext: COX) announced Wednesday August 26, 2026 that the FDA accepted the New Drug Application for NCX 470 (bimatoprost-nitric oxide donor, a once-daily topical eye drop for the reduction of intraocular pressure in open-angle glaucoma or ocular hypertension) with a PDUFA target action date of April 30, 2027. NCX 470 combines the FDA-approved prostaglandin analog bimatoprost with a nitric-oxide-releasing moiety intended to add trabecular meshwork outflow to the standard uveoscleral outflow mechanism, and completed two positive Phase 3 studies (Mont Blanc and Denali). Not a peptide, but the readout matters as ophthalmology continues to be a Phase 3 register hub for peptide programs (Palatin's PL9643 melanocortin-4 receptor agonist for dry eye) that would follow the same combination-with-standard-of-care commercial pattern if approved.
Johnson & Johnson (NYSE: JNJ) received FDA approval Wednesday August 26, 2026 for Imaavy (nipocalimab), an anti-neonatal Fc receptor (FcRn) monoclonal antibody administered as subcutaneous injection, for the treatment of warm autoimmune hemolytic anemia (wAIHA) in adults and pediatric patients aged 12 and older. Disease context: wAIHA is a rare autoimmune disease in which autoantibodies (primarily IgG) bind red blood cells at body temperature and trigger complement- and macrophage-mediated red blood cell destruction, causing fatigue, jaundice, splenomegaly, and in severe cases life-threatening anemia. Prior treatment has relied on corticosteroids, rituximab (an anti-CD20 monoclonal antibody), splenectomy, and other immunosuppressants, all with substantial side effects and variable efficacy. Nipocalimab mechanism: blocks the neonatal Fc receptor (FcRn) that normally rescues IgG antibodies from degradation; blocking FcRn accelerates IgG catabolism and reduces the pathogenic IgG autoantibody burden that drives wAIHA. The Imaavy approval extends the anti-FcRn therapeutic category that argenx pioneered with Vyvgart (efgartigimod alfa, IV and SC formulations) into a new autoimmune indication beyond the currently-approved indications of generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The FcRn category is a growing modality with multiple companies pursuing autoimmune indications; J&J's Imaavy is now approved for wAIHA and separately in myasthenia gravis, positioning as a direct competitor to argenx's Vyvgart franchise. Approval was supported by Phase 3 clinical data documenting substantial improvements in hemoglobin levels and transfusion-independence rates compared to placebo.
Jazz Pharmaceuticals (NASDAQ: JAZZ) and Zymeworks (NASDAQ: ZYME) received FDA approval Tuesday August 25, 2026 for Ziihera (zanidatamab-hrii, an anti-HER2 bispecific monoclonal antibody) in combination regimens for first-line treatment of adult patients with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA). Approved regimens: Ziihera with chemotherapy (fluoropyrimidine and platinum), and Ziihera with tislelizumab (BeiGene's anti-PD-1 monoclonal antibody) plus chemotherapy. Trial basis: Phase 3 HERIZON-GEA-01 documented median overall survival of more than two years. Ziihera mechanism: zanidatamab-hrii is a bispecific antibody that binds two distinct epitopes on HER2 simultaneously, producing higher-affinity target engagement, receptor clustering, and immune-mediated tumor cell killing versus conventional monospecific anti-HER2 antibodies. The approval triggers a $250 million milestone payment from Jazz to Zymeworks, with Zymeworks remaining eligible for up to $1.3 billion in additional milestones plus tiered royalties of up to 20% on net sales. Jazz expects to launch Ziihera commercially in the US in this indication. The approval extends the Ziihera commercial franchise beyond its earlier accelerated approval in biliary tract cancer to a substantially larger commercial indication in HER2-positive GEA. GEA is a globally common cancer with roughly 22,000 US cases per year and substantially higher incidence in Asia; roughly 15-25% of GEA cases express HER2, defining the addressable population. The result is a positive readout for the bispecific antibody modality more broadly.
Regenxbio (NASDAQ: RGNX) shares fell approximately 25% to $8.05 Tuesday August 25, 2026 after the FDA placed a clinical hold on the RGX-121 gene therapy program for the treatment of Mucopolysaccharidosis type II (MPS II, also known as Hunter Syndrome). Disease context: MPS II is a rare X-linked lysosomal storage disease affecting approximately 1 in 100,000-170,000 male births globally, caused by iduronate-2-sulfatase (IDS) enzyme deficiency that results in accumulation of glycosaminoglycans (GAGs) in multiple tissues including the central nervous system. Clinical manifestations include progressive cognitive decline, skeletal abnormalities, cardiac and respiratory involvement, and reduced life expectancy in the severe neuronopathic form (approximately two-thirds of patients). RGX-121 mechanism: an AAV (adeno-associated virus) gene therapy delivering an IDS-encoding transgene via intracerebroventricular administration designed to establish stable IDS expression in the central nervous system, addressing the neurocognitive manifestations that the currently-approved enzyme replacement therapy Elaprase (idursulfase, Takeda) does not reach because Elaprase administered intravenously does not cross the blood-brain barrier. Specific reasons for the FDA clinical hold have not been publicly disclosed by Regenxbio; details are expected in subsequent regulatory correspondence. The clinical hold delays but does not necessarily preclude the RGX-121 development pathway. Regenxbio's broader pipeline includes RGX-202 for Duchenne muscular dystrophy in Phase 3, RGX-314 for wet AMD in Phase 3, and multiple additional gene therapy candidates.
Gilead Sciences (NASDAQ: GILD) received European Commission marketing authorization Monday August 24, 2026 for Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) for first-line treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). Approval criteria: PD-L1 combined positive score (CPS) ≥10 and no prior systemic therapy for metastatic disease. Trodelvy mechanism: an antibody-drug conjugate (ADC) with an anti-Trop-2 monoclonal antibody linked to the SN-38 topoisomerase I inhibitor payload; when Trop-2 (trophoblast cell surface antigen 2) is expressed on tumor cells, Trodelvy binds and internalizes to release the cytotoxic SN-38 inside the cancer cell. The Keytruda addition provides checkpoint inhibitor activity against PD-L1-positive tumors. Positioning: the first and only antibody-drug conjugate plus immunotherapy combination approved for first-line metastatic TNBC in the EU's 27 member states, plus Norway, Iceland, and Liechtenstein. The FDA had already approved the same combination in June 2026 based on the same clinical evidence. The approval extends Gilead's ADC commercial franchise. The ADC combination-therapy category (ADC + checkpoint inhibitor, ADC + targeted therapy) has attracted increasing investment across oncology as ADCs establish clinical value across breast, bladder, lung, and other solid tumors; adjacent peptide-drug conjugates (PDCs) with tumor-targeting peptides plus cytotoxic payloads are also expanding as a related modality.
Capricor Therapeutics (NASDAQ: CAPR) faced its Prescription Drug User Fee Act (PDUFA) target action date Saturday August 22, 2026 for deramiocel (a cardiosphere-derived allogeneic cell therapy, not a peptide) in Duchenne muscular dystrophy (DMD) cardiomyopathy. Background: the FDA issued a Complete Response Letter (CRL) in July 2025 citing that the Phase 2 data supporting the cell therapy fell short of the statutory requirement for substantial evidence of effectiveness. Capricor reported positive Phase 3 HOPE-3 trial results in December 2025 meeting both primary and secondary endpoints, and the FDA accepted the resubmission in March 2026 with a Class 2 resubmission classification and August 22 target action date. The July 29, 2026 FDA Cellular, Tissue, and Gene Therapies Advisory Committee voted 9-3 that available evidence does not provide substantial evidence of effectiveness to recommend approval. Panel members cited concerns about the stability of the statistical results, with left ventricular ejection fraction (LVEF) endpoint outcomes appearing highly sensitive to how missing data were handled and which analytic assumptions were applied. A second Complete Response Letter is the expected outcome, and CAPR stock slipped in advance of the decision on elevated volume as investors positioned for the anticipated regulatory rejection. Duchenne muscular dystrophy affects approximately 20,000 US patients (predominantly boys with X-linked inheritance) and progressive cardiomyopathy is the leading cause of death in the DMD population. The DMD cardiomyopathy indication remains without an FDA-approved therapy. Capricor holds Rare Pediatric Disease Designation for deramiocel, which may qualify the company for a Priority Review Voucher upon eventual approval if it comes.
Capricor Therapeutics (NASDAQ: CAPR) faced its PDUFA target action date Saturday August 22, 2026 for deramiocel (a cardiosphere-derived allogeneic cell therapy, not a peptide) in the treatment of Duchenne muscular dystrophy (DMD) cardiomyopathy. Background: the FDA issued a Complete Response Letter (CRL) in July 2025 citing that the Phase 2 data supporting the cell therapy fell short of the statutory requirement for substantial evidence of effectiveness. Capricor reported positive Phase 3 HOPE-3 trial results in December 2025 meeting both primary and secondary endpoints, and the FDA accepted the resubmission in March 2026 with a Class 2 resubmission classification and August 22 target action date. The July 29, 2026 FDA Cellular, Tissue, and Gene Therapies Advisory Committee voted 9-3 that available evidence does not provide substantial evidence of effectiveness to recommend approval. Panel members cited concerns about the stability of the statistical results, with left ventricular ejection fraction (LVEF) endpoint outcomes appearing highly sensitive to how missing data were handled and which analytic assumptions were applied. A second Complete Response Letter is the expected outcome. Duchenne muscular dystrophy affects approximately 20,000 US patients (predominantly boys with X-linked inheritance) and progressive cardiomyopathy is the leading cause of death in the DMD population. The DMD cardiomyopathy indication remains without an FDA-approved therapy, which continues the substantial unmet need in the space. Capricor holds Rare Pediatric Disease Designation for deramiocel, which may qualify the company for a Priority Review Voucher upon eventual approval if it comes.
Capricor Therapeutics (NASDAQ: CAPR) faces its Prescription Drug User Fee Act (PDUFA) target action date Saturday August 22, 2026 for deramiocel (a cardiosphere-derived cell therapy, not a peptide) in the treatment of Duchenne muscular dystrophy (DMD) cardiomyopathy. Background: the FDA issued a Complete Response Letter (CRL) in July 2025 citing that the Phase 2 data supporting the cell therapy fell short of the statutory requirement for substantial evidence of effectiveness. Capricor reported positive Phase 3 HOPE-3 trial results in December 2025 meeting both primary and secondary endpoints, and the FDA accepted the resubmission in March 2026 with a Class 2 resubmission classification and August 22 target action date. The July 29, 2026 FDA Cellular, Tissue, and Gene Therapies Advisory Committee voted 9-3 that available evidence does not provide substantial evidence of effectiveness to recommend approval. Panel members cited concerns about the stability of the statistical results, saying that left ventricular ejection fraction (LVEF) endpoint outcomes appeared highly sensitive to how missing data were handled and which analytic assumptions were applied. A second Complete Response Letter is the expected outcome. Duchenne muscular dystrophy affects approximately 20,000 US patients (predominantly boys with X-linked inheritance) and progressive cardiomyopathy is the leading cause of death in the population. The DMD cardiomyopathy indication remains without an FDA-approved therapy.
Hengrui Pharma disclosed Saturday August 22, 2026 that China's Center for Drug Evaluation (CDE) granted implied license for HRS-4729 in metabolic dysfunction-associated fatty liver disease (MAFLD) and hepatitis. The CDE implied license is a Chinese regulatory instrument that provides approval to initiate human clinical trials in China under a simplified pathway (similar in function to a US Investigational New Drug application, though procedurally different). HRS-4729's specific molecular mechanism has not been publicly disclosed in detail; the MAFLD/hepatitis indication placement suggests likely mechanisms include FGF21 analog, thyroid hormone receptor beta agonist, or a novel liver-target mechanism. The disclosure extends Hengrui's cardiometabolic pipeline beyond its existing ribupatide (once-weekly injectable GLP-1/GIP/glucagon triple agonist licensed ex-China to Kailera Therapeutics for global Phase 3 initiation in H1 2027) into the growing MASH commercial category. MASH commercial market context: the category is anchored by Madrigal Pharmaceuticals' Rezdiffra (resmetirom, a thyroid hormone receptor beta agonist and the first FDA-approved MASH drug, approved March 2024) and Novo Nordisk's Wegovy (semaglutide 2.4 mg received FDA accelerated approval for non-cirrhotic MASH with moderate-to-advanced fibrosis in August 2025). The Hengrui advance into MAFLD/hepatitis positions the company for a potential fourth cardiometabolic franchise beyond obesity, type 2 diabetes, and cardiovascular disease.
Regeneron Pharmaceuticals (NASDAQ: REGN) received FDA approval Thursday August 20, 2026 for Pasatru (garetosmab-grts, an anti-activin A monoclonal antibody administered as subcutaneous injection) for the reduction of the formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). FOP is a rare autosomal-dominant genetic disease affecting roughly 1 in 2 million people globally (approximately 800 patients in the US) in which skeletal muscle and connective tissue progressively turn into bone through extra-skeletal ossification triggered by activin A signaling through mutated ACVR1 (activin receptor A type 1) receptors. Patients typically develop the first flare-ups in early childhood, with progressive immobilization by adulthood as ossification advances across major joints. Pasatru's mechanism: garetosmab binds activin A and blocks its signaling through the mutated ACVR1 receptors, reducing the flare-up frequency and slowing new HO lesion formation. The approval marks the second FDA-approved therapy for FOP after Ipsen's Sohonos (palovarotene, a retinoic acid receptor gamma agonist small molecule) approved in 2023. Pasatru offers a mechanistically distinct alternative for patients who cannot tolerate palovarotene or who need combination or sequential therapy. The Pasatru approval extends Regeneron's growing rare-disease commercial portfolio alongside Eylea (aflibercept for wet AMD), Dupixent (dupilumab for atopic dermatitis and asthma), and multiple antibody-drug conjugate programs in development. Pricing and launch details have not been publicly disclosed but rare-disease pricing typically runs $300,000-$500,000 per patient per year.